Sinovac said on Monday (18) Monday that Coronavac’s effectiveness in his clinical trial in Brazil was almost 20 percentage points higher in a small group of participants who took the second dose after a longer period. Information from Reuters.
The protection rate of 1,394 participants who received a second dose of vaccine or placebo three weeks apart was almost 70%, according to a company spokesperson.
Most trial participants in Brazil received the second dose 14 days later.
Last week, Ricardo Palácios, Bhutantan’s director of medical clinical research, said at a press conference that the immune response could improve with longer intervals between the first and second doses.